Poster Session I: Basic science: biomarkers, imaging and lipids

Abstract

P115 The effects of atorvastatin and micronized fenofibrate on endothelial functions in metabolic syndrome patients: comparative study MD Demir Hakan, MD Ural Dilek, MD Kozdag Guliz, MD Ertas Gokhan, MD Tayfun Sahin, MD Oner Gokhan, MD Ulas Bildirici Department of Cardiology, Kocaeli, Turkey Topic: Obesity Objective:To compare the effects of atorvastatin 10 mg/day andmicronized fenofibrate 200 mg/ day on traditional and non-traditional risk and endothelial functions in patients with metabolic syndrome. Materials and Methods: Sixty-five consecutive patients who were free of coronary artery were studied. Patients were randomized to atorvastatin 10 mg/da yor micronized fenofibrate 200 mg/ day. At entry and end of the study; blood and urine samples were collected fort he biochemical analyses and brachial artery reactivity and carotis intima-media thicknes were measured using high resolution ultrasonography. Results: A total of 52 patients completed the study. With both drugs; treatment goals of total cholesterol, LDL cholesterol, HDL cholesterol and nonHDL cholesterol was reached similarly. CRP reductions were significant in both groups (p1⁄40.041 vs p1⁄40.003) By fenofibrate; while levels of fibrinogen, uric acid and inslin were significantly declined and HOMA index was reduced (p1⁄4 0.003, p<0,001, ; p1⁄40.001, p1⁄4 0.002 respectively), a significant rise in the homocystein levels was observed (p1⁄40.015). In each groups; significant (p1⁄40,002 for atorvastatin and p1⁄40.022 for fenofibrate) and similar improvements occured on flow-mediated dilation of the brachial artery. Conclusion: Treatment with atorvastatin 10 mg/day or micronized fenofibrate 200 mg/day during six months have similar benefical effects on endothelial vasomotor functions inmetabolic syndrome with desirable side effects. Both reduce CRP levels significantly and similarly. While atorvastatin is more effective on LDL cholesterol and total cholesterol, fenofibrate is more effective on inslin resistance and the serum markers of endothelial dysfunction. Both drugs are good treatment options in metabolic syndrome, however lipid status of the patient and the other markers of atherosclerosis should also be considered while selecting the more suitable agent. Combination therapy must be kept in mind with close monitoring of the side effects.